Medical Director, UT Southwestern Simmons Cancer Center Plano Richardson, Richardson TX
Oncology
Dr. Klaus Hollmig, MD
|
|
Give Review
Klaus Hollmig is an expert in the field of Oncology. He researched medicine at University of Alabama Medical Center. University of Alabama Medical Center is ranked 37 in research and 17 in primary care medicine He received awards:"Meaningful Use Stage 1 Certification". Dr. Klaus Hollmig is a published doctor. He has 27 publications published. The most current publication "[Effect of rhG-CSF on platelets using in vitro bleeding time and transcranial Doppler examination]." Klaus Hollmig accepts Medicare payments and is listed with Medicare.gov.
Publications
- Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic Leukemia.
- Long-term survival of recipients of allogeneic bone-marrow transplantation after mechanical ventilation.
- Acquired factor VIII inhibitors in nonhemophilic patients.
- Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.
- Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12.
- Dialysis-dependent renal failure in patients with Myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
- [Effect of rhG-CSF on platelets using in vitro bleeding time and transcranial Doppler examination].
- Complete remission in multiple Myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
- Gene expression profiling of plasma cells at Myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
- Seven-year median time to progression with thalidomide for smoldering Myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic dis...
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in Myeloma patients with metaphase cytogenetic abnormalities.
- Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple Myeloma.
- Benefit of complete response in multiple Myeloma limited to high-risk subgroup identified by gene expression profiling.
- Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple Myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas...
- Incorporating bortezomib into upfront treatment for multiple Myeloma: early results of total therapy 3.
- Testing standard and genetic parameters in 220 patients with multiple Myeloma with complete data sets: superiority of molecular genetics.
- High serum-free light chain levels and their rapid reDuction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
- Magnetic resonance imaging in multiple Myeloma: diagnostic and clinical implications.
- Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering Disease.
- A validated gene expression model of high-risk multiple Myeloma is defined by deregulated expression of genes mapping to chromosome 1.
- Gene-expression signature of benign monoclonal gammopathy evident in multiple Myeloma is linked to good prognosis.
- Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple Myeloma.
- The molecular classification of multiple Myeloma.
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed Myeloma and i...
- Thalidomide and hematopoietic-cell transplantation for multiple Myeloma.
- Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified inDuction and posttransplantation consolidation therapies.
Schools
Rheinischen Friedrich Wilhelms Universitaet Bonn Medizinische Fakultat
University Mo
University Ala
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Alabama Medical Center -
University of Missouri-Columbia -
University of Bonn Faculty of Medicine
Hospital
-
University of Texas Southwestern Medical Center
Drug Facts
| NPI NUMBER | 1083704563 | |
| NPPES Provider LastName | HOLLMIG | |
| NPPES Provider FirstName | KLAUS | |
| NPPES Provider ZIPCode | 753907201 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 153.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083704563 |
| Last Name Of The Provider | HOLLMIG |
| First Name Of The Provider | KLAUS |
| View All |
Similar Doctors
|
|
Dr. Robert G. Mennel, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. John E. Pippen Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia R. Osborne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joan H. Schiller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vinay K. Jain, MD |
|
|
Dr. Debra L. Caudy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sophie W. Sun, MD |
|
|
Dr. James B. Brugarolas, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. James F. Amatruda, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jiu Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sirisha Karri, MD
This Doctor is OpenDoctor Recommended.
|